PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases

نویسندگان

چکیده

Therapeutic strategies for epithelial ovarian cancers are evolving with the advent of immunotherapy, such as PD-L1 inhibitors, encouraging results. However, little data available on PDL-1 expression in cancers. Thus, we set out to determine according histological subtype. We evaluated two clones – QR1 and E1L3N scores, one based percentage labeled tumor cells (tumor proportion score, TPS) other immune (combined CPS) a consecutive retrospective series 232 was more frequent high grade serous carcinoma (27.5% clone 41.5% clone), 3 endometrioid (25% 50% clear-cell carcinomas (27.3% 29.6% clone) than subtypes CPS score. Using 17% cases were vs 28% QR1. TPS 14% positive For CPS, respectively, 77% 78% concordant thresholds 1%. Overall progression-free survival between negative patients not different across all types, each subtype particular expressing PD-L1. Expression is relatively uncommon epithelium tumors. When positive, usually <10% labeled. appear best tools evaluate expression.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer

Endometrial cancer (EC) is the most frequent gynecological malignancy and a major cause of morbidity and mortality for women worldwide. Programmed cell death protein 1 (PD-1) and its ligands programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2) have been well studied in lung cancer, melanoma and renal-cell cancer. However, few studies have been performed in EC. The purpose of ...

متن کامل

a comparison of teachers and supervisors, with respect to teacher efficacy and reflection

supervisors play an undeniable role in training teachers, before starting their professional experience by preparing them, at the initial years of their teaching by checking their work within the proper framework, and later on during their teaching by assessing their progress. but surprisingly, exploring their attributes, professional demands, and qualifications has remained a neglected theme i...

15 صفحه اول

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.

The programmed death 1 (PD-1) receptor and its ligands programmed death ligand 1 (PD-L1) and PD-L2, members of the CD28 and B7 families, play critical roles in T cell coinhibition and exhaustion. Overexpression of PD-L1 and PD-1 on tumor cells and tumor-infiltrating lymphocytes, respectively, correlates with poor disease outcome in some human cancers. Monoclonal antibodies (mAbs) blockading the...

متن کامل

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.

Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive antitumor activity. Patients with tumors expressing PD-L1 are most likely to respond to this treatment. The aim of our study was to develop a noninvasive imaging technique to determine tumor PD-L1 expression in vivo. This could allow selection of patients that are most likely to benefi...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: European Journal of Histochemistry

سال: 2021

ISSN: ['2038-8306', '1121-760X']

DOI: https://doi.org/10.4081/ejh.2021.3185